跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Ascendis Pharma Growth Disorders A/S

首页临床试验发起方与机构Ascendis Pharma Growth Disorders A/S

Ascendis Pharma Growth Disorders A/S

ACTIVE

Tuborg Boulevard 12, Hellerup, Hovedstaden, 丹麦Subsidiary

隶属于 Ascendant Resources Inc

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

20

11 进行中

药物批准

0

批准总数

监管机构

0

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

12

60.0%

2 期

8

40.0%

试验状态分布

进行中（未招募）

10

50.0%

已完成

2

10.0%

Enrolling By Invitation

1

5.0%

招募中

7

35.0%

相关临床试验

该机构主办的试验（20）

A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia

进行中（未招募）

Jul 202422 名受试者

COACH: A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children with Achondroplasia

Dec 202318 名受试者

A Phase 2 Clinical Trial to Investigate Safety, Tolerability and Efficacy of TransCon CNP, Weekly Subcutaneous Injections, Compared with Placebo, in Infants with Achondroplasia.

进行中（未招募）

Dec 202372 名受试者

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

Enrolling By Invitation

Jun 2023140 名受试者

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia

Mar 202384 名受试者

AttaCH: A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents with Achondroplasia

Feb 2023113 名受试者

A phase 2b clinical trial to evaluate efficacy and safety of weekly doses of TransCon CNP compared with placebo in participants with achondroplasia aged 2 to 11 years of age

进行中（未招募）

Dec 202280 名受试者

A phase 2b clinical trial to evaluate efficacy and safety of weekly doses of TransCon CNP compared with placebo in participants with achondroplasia aged 2 to 11 years of age

Nov 202280 名受试者

第 1 页，共 3 页

药物批准

暂无批准数据

资讯

暂无资讯文章

本页目录

概览
相关临床试验20
药物批准
资讯

返回机构列表